Technology Overview

Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: the TG platform are neo-antigen cancer vaccines designed to specifically treat tumors that express mutated forms of RAS, and ONCOS-102 is a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.

Both treatment approaches harness the patient’s own immune system to fight the cancer.

Read more about Virus-based Immunotherapy (ONCOS-102)

Read more about Neo-antigen targeted Immunotherapy (TG01)

Targovax brings together two unique & complementary immuno-oncology technologies